Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicity

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 2, 2012, Pages 227-233

  Wood, David M ^a,b   Dargan, Paul I ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

4 Methylmethcathinone; Mephedrone; Poisoning; Recreational drugs; Toxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; AMPHETAMINE; COCAINE; DOPAMINE; SEROTONIN;

ACUTE TOXICITY; ARTICLE; DRUG ABUSE; DRUG CONTROL; DRUG DETERMINATION; EMERGENCY WARD; EXPERIMENTAL ANIMAL; HEALTH SURVEY; HUMAN; INTOXICATION; NONHUMAN; POPULATION RESEARCH; PREVALENCE; SEIZURE;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG AND NARCOTIC CONTROL; HUMANS; METHAMPHETAMINE; MODELS, ANIMAL; PREVALENCE;

EID: 84866986754     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.04.020     Document Type: Article

References (72)

1. Adebamiro A., Perazella M.A. Recurrent acute kidney injury following bath salts intoxication. Am J Kidney Dis 2012, 59:273-275.
2. Angoa-Pérez M., Kane M.J., Francescutti D.M., Sykes K.E., Shah M.M., Mohammed A.M., Thomas D.M., Kuhn D.M. Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem 2011, 120:1097-1107.
3. Baumann M.H., Ayestas M.A., Partilla J.S., Sink J.R., Shulgin A.T., Daley P.F., et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37:1192-1203.
4. Bell C., George C., Kicman A.T., Traynor A. Development of a rapid LC-MS/MS method for direct urinalysis of designer drugs. Drug Test Anal 2011, 3:496-504.
5. Brandt S.D., Sumnall H.R., Measham F., Cole J. Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal 2010, 2:377-382.
6. Brandt S.D., Sumnall H.R., Measham F., Cole J. Second generation mephedrone. The confusing case of NRG-1. BMJ 2010, 341:c3564.
7. Bruno R., Matthews A.J., Dunn M., Alati R., McIlwraith F., Hickey S., Burns L., Sindicich N. Emerging psychoactive substance use among regular ecstasy users in Australia. Drug Alcohol Depend 2012, 124:19-25.
8. Brunt T.M., Poortman A., Niesink R.J., van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 2011, 25:1543-1547.
9. Carhart-Harris R.L., King L.A., Nutt D.J. A web-based survey on mephedrone. Drug Alcohol Depend 2011, 118:19-22.
10. Camilleri A., Johnston M.R., Brennan M., Davis S., Caldicott D.G. Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone. Forensic Sci 2010, 197:59-66.
11. Centers for Disease Control, Prevention (CDC) Emergency department visits after use of a drug sold as "bath salts"-Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep. 2011, 60:624-627.
12. Council Decision Council decision of 2 December 2010 on submitting 4-methylmethcathinone (mephedrone) to control measures (2010/759/EU) 2010.
13. Dargan P.I., Wood D.M. Annex 1 to the risk assessment report: technical report on mephedrone. EMCDDA contract CT.10.EPI.057. July 2010 2010, Available from:, http://www.ofdt.fr/BDD/publications/docs/rarOEDTmephAnn1.pdf [Last accessed 19th April 2012].
14. Dargan P.I., Albert S., Wood D.M. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 2010, 103:875-879.
15. Dargan P.I., Sedefov R., Gallegos A., Wood D.M. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test Anal 2011, 3:454-463.
16. Davies S., Wood D.M., Smith G., Button J., Ramsey J., Archer R., et al. Purchasing 'legal highs' on the Internet-is there consistency in what you get?. QJM 2010, 103:489-493.
17. Dick D., Torrance C. Drugs survey. MixMag 2010, 225:44-53.
18. Drug Enforcement Administration, Department of Justice Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final order. Fed Regist 2011, 76:65371-65375.
19. Drugs forum: mephedrone and beta-ketones. Available from: [Last accessed 19th April 2012]. http://www.drugs-forum.com/forum/forumdisplay.php?f=377.
20. Elie L., Baron M., Croxton R., Elie M. Microcrystalline identification of selected designer drugs. Forensic Sci Int 2012, 214:182-188.
21. EMCDDA-Europol Joint Report Joint report on a new psychoactive substance: 4-methylmethcathinone (mephedrone) 2010, Reference 8145/10. Cordrogue 36 San 68. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_102496_EN_Europol-EMCDDA_Joint_Report_Mephedrone.pdf [Last accessed 19th April 2012].
22. EMCDDA Drug Profile EMCDDA - drug profiles: synthetic cathinones 2010, Available from: http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones [Last accessed 19th April 2012].
23. EMCDDA Annual report on the state of the drugs problem in Europe (2011). Available from: [Last accessed 19th April 2012]. http://www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCDDA_AR2011_EN.pdf.
24. Erowid 4-methylmethcathinone/mephedrone Available from: [Last accessed 19th April 2012]. http://www.erowid.org/chemicals/4_methylmethcathinone/4_methylmethcathinone.shtml.
25. EWS guidelines EMCDDA, 2007. Early-warning system on new psychoactive substances - operating guidelines 2007, Publications Office of the European Union, Luxembourg, Also available at: http://www.emcdda.europa.eu/html.cfm/index52448EN.html [Last accessed 19th April 2012].
26. Gibbons S., Zloh M. An analysis of the 'legal high' mephedrone. Bioorg Med Chem Lett 2010, 20:4135-4139.
27. Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Ellis J.D., Allen S.C., et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011, 339:530-536.
28. Hägerkvist R., Hultén P., Personne M. Increasing abuse of new cathinone derivatives in Sweden - a poisons centre study for the years 2008-2009. Clin Toxicol 2010, 48:291-292.
29. Hillebrand J., Olszewski D., Sedefov R. Legal highs on the Internet. Subst Use Misuse 2010, 45:330-340.
30. Home Office Statistical Bulletin. Drug Misuse Declared: Findings from the 2010/11 British Crime Survey (2011) [Last accessed 19th April 2012]. http://www.homeoffice.gov.uk/publications/science-research-statistics/research-statistics/crime-research/hosb1211/hosb1211?view=Binary.
31. James D., Adams R.D., Spears R., Cooper G., Lupton D.J., Thompson J.P., et al. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 2011, 28:686-689.
32. Jankovics P., Váradi A., Tölgyesi L., Lohner S., Németh-Palotás J., Koszegi-Szalai H. Identification and characterization of the new designer drug 4'-methylethcathinone (4-MEC) and elaboration of a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) screening method for seven different methcathinone analogs. Forensic Sci Int 2011, 210:213-220.
33. Kasick D.P., McKnight C.A., Klisovic E. "Bath salt" ingestion leading to severe intoxication delirium: two cases and a brief review of the emergence of mephedrone use. Am J Drug Alcohol Abuse 2012, 38:176-180.
34. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., et al. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 2011, 164:1949-1958.
35. Lea T., Reynolds R., De Wit J. Mephedrone use among same-sex attracted young people in Sydney, Australia. Drug Alcohol Rev 2011, 30:438-440.
36. Lusthof K.J., Oosting R., Maes A., Verschraagen M., Dijkhuizen A., Sprong A.G. A case of extreme agitation and death after the use of mephedrone in The Netherlands. Forensic Sci Int 2011, 206:e93-95.
37. Martin M., Muller J.F., Turner K., Duez M., Cirimele V. Evidence of mephedrone chronic abuse through hair analysis using GC/MS. Forensic Sci Int 2012, 218:44-48.
38. Martínez-Clemente J., Escubedo E., Pubill D., Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 2012, 22:231-236.
39. McDermott S.D., Power J.D., Kavanagh P., O'Brien J. The analysis of substituted cathinones. Part 2: an investigation into the phenylacetone based isomers of 4-methylmethcathinone and N-ethylcathinone. Forensic Sci Int 2011, 212:13-21.
40. McElrath K., O'Neill C. Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. Int J Drug Policy 2011, 22:120-127.
41. Measham F., Moore K., Newcombe R., Welch Z. Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition. Drugs Alcohol Today 2010, 10:14-21.
42. Measham F., Wood D.M., Dargan P.I., Moore K. The rise in legal highs: prevalence and patterns in the use of illegal drugs and first- and second-generation "legal highs" in South London gay dance clubs. J SubsUse 2011, 16:263-272.
43. Measham F., Moore K., Østergaard J. Mephedrone, 'bubble' and unidentified white powders: the contested identities of synthetic 'legal highs'. Drugs and Alcohol Today 2011, 11:137-147.
44. Meng H., Cao J., Kang J., Ying X., Ji J., Reynolds W., et al. Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat. Toxicol Lett 2012, 208:62-68.
45. Motbey C.P., Hunt G.E., Bowen M.T., Artiss S., McGregor I.S. Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol 2012, 17:409-422.
46. Meyer M.R., Wilhelm J., Peters F.T., Maurer H.H. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 2010, 397:1225-1233.
47. Newcombe, R. (2009). Mephedrone. The use of mephedrone (M-cat, Meow) in Middlesbrough. Lifeline Publications and Research: Manchester, UK. Available from: [Last accessed 19th April 2012]. http://www.lifeline.org.uk/docs/M-cat%20report%20small.pdf.
48. Nicholson P.J., Quinn M.J., Dodd J.D. Headshop heartache: acute mephedrone 'meow' myocarditis. Heart 2010, 96:2051-2052.
49. Petróczi A., Nepusz T., Cross P., Taft H., Shah S., Deshmukh N., et al. New non-randomised model to assess the prevalence of discriminating behaviour: a pilot study on mephedrone. Subst Abuse Treat Prev Policy 2011, 6:20.
50. Power J.D., McGlynn P., Clarke K., McDermott S.D., Kavanagh P., O'Brien J. The analysis of substituted cathinones. Part 1: chemical analysis of 2-, 3- and 4-methylmethcathinone. Forensic Sci Int 2011, 212:6-12.
51. Prosser J.M., Nelson L.S. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012, 8:33-42.
52. Psychonaut WebMapping Research Group (2009). Mephedrone Report. Institute of Psychiatry, King's College London: London, UK Available from: [Last accessed 19th April 2012]. http://194.83.136.209/documents/reports/Mephedrone.pdf.
53. Ramsey J., Dargan P.I., Smyllie M., Davies S., Button J., Holt D.W., et al. Buying 'legal' recreational drugs does not mean that you are not breaking the law. QJM 2010, 103:777-783.
54. Ramoz L., Lodi S., Bhatt P., Reitz A.B., Tallarida C., Tallarida R.J., et al. Mephedrone ("bath salt") pharmacology: insights from invertebrates. Neuroscience 2012, 19:79-84.
55. Regan L., Mitchelson M., Macdonald C. Mephedrone toxicity in a Scottish emergency department. EMJ 2011, 28:1055-1058.
56. Reitzel L.A., Dalsgaard P.W., Müller I.B., Cornett C. Identification of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish Internet company. Drug Test Anal 2012, 4:342-354.
57. Sammler E.M., Foley P.L., Lauder G.D., Wilson S.J., Goudie A.R., O'Riordan J.I. A harmless high?. Lancet 2010, 376:742.
58. Santali E.Y., Cadogan A.K., Daeid N.N., Savage K.A., Sutcliffe O.B. Synthesis, full chemical characterisation and development of validated methods for the quantification of (±)-4'-methylmethcathinone (mephedrone): a new "legal high". J Pharm Biomed Anal 2011, 56:246-255.
59. Schifano F., Albanese A., Fergus S., Stair J.L., Deluca P., Corazza O., Davey Z., Corkery J., Siemann H., Scherbaum N., Farre M., Torrens M., Demetrovics Z., Ghodse A.H., Psychonaut Web Mapping, ReDNet Research Groups Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 2011, 214:593-602.
60. Shah S.A., Deshmukh N.I., Barker J., Petróczi A., Cross P., Archer R., et al. Quantitative analysis of mephedrone using liquid chromatography tandem mass spectroscopy: application to human hair. J Pharm Biomed Anal 2012, 61:64-69.
61. Sørensen L.K. Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid-chromatography-electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:727-736.
62. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol (Phila) 2011, 49:499-505.
63. Winstock A., Mitcheson L., Marsden J. Mephedrone: still available and twice the price. Lancet 2010, 376:1537.
64. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
65. Winstock A. Drugs survey. MixMag 2011, 238:49-59.
66. Winstock A., Mitcheson L., Ramsey J., Davies S., Puchnarewicz M., Marsden J. Mephedrone: use, subjective effects and health risks. Addiction 2011, 106:1991-1996.
67. Wong M.L., Holt R.I. The potential dangers of mephedrone in people with diabetes: a case report. Drug Test Anal 2011, 3:464-465.
68. Wood D.M., Davies S., Puchnaewicz M., Button J., Archer R., Ovaska H., et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 2010, 6:327-330.
69. Wood D.M., Greene S.L., Dargan P.I. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 2011, 28:280-282.
70. Wood D.M., Davies S., Greene S.L., Button J., Holt D.W., Ramsey J., et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol 2010, 48:924-927.
71. Wood DM, Greene SL, Dargan PI. Emergency department presentations in determining the effectiveness of drug control in the United Kingdom:mephedrone (4-methylmethcathinone) control appears to be effective using this model. Emerg Med J in press.
72. Wood D.M., Measham F., Dargan P.I. 'Our favourite drug': prevalence of use and preference for mephedrone in the London night-time economy 1year after control. J Subs Use 2012, 17:91-97.